Feasibility of Multi-modality Central Nervous System Evaluation in HER2+ Breast Cancer Patients
概览
- 阶段
- 不适用
- 干预措施
- MRI
- 疾病 / 适应症
- Breast Cancer
- 发起方
- Memorial Sloan Kettering Cancer Center
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Percentage of eligible patients completing cerebrospinal fluid (CSF) evaluation
- 状态
- 进行中（未招募）
- 最后更新
- 3个月前
概览
简要总结
The researchers doing this study think that performing scans of the brain and testing cerebrospinal fluid (CSF) in people with HER2-positive breast cancer may be an effective way of identifying the early onset of CNS metastases (such as brain cancer). If the researchers can identify the early onset of CNS metastases, they can immediately treat that cancer and possibly prevent it from worsening. Currently, people with breast cancer don't usually have scans of the brain or CSF testing unless they are experiencing symptoms of CNS metastases.
研究者
入排标准
入选标准
- •Patients with Stage IV metastatic HER2+ breast cancer without CNS disease s/p 1 or more lines of HER2 directed therapy (Cohort A Only)
- •Patients with Stage II-III HER2+ breast cancer without CNS disease (Cohort B Only)
- •Male and Female participants Age ≥18 years
- •HER2+ as defined by ASCO/CAP guidelines\*
- •Ability to undergo bedside Lumbar puncture to obtain cerebrospinal fluid; if beside LP is not successful due to patient discomfort or inability to obtain spinal fluid then patients will be offered LP through interventional radiology and patients will continue to be monitored on study
- •Patients with breast implants and/or tissue expanders are eligible if they are able to safely undergo an MRI
- •Able to provide written informed consent \*ASCO/CAP guidelines: HER2+ defined as IHC 3+ positive and/or by ISH average copy number ≥ 6 signals/cell
排除标准
- •Patients who are unable to undergo MRI with gadolinium
- •Patients with CNS Metastases on Screening MRI
- •Patients with Positive Cytology on Screening Bedside lumbar puncture
研究组 & 干预措施
Stage IV HER2+ breast cancer
Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
干预措施: MRI
Stage IV HER2+ breast cancer
Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
干预措施: Lumbar puncture
Stage II-III HER2+ breast cancer
Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
干预措施: MRI
Stage II-III HER2+ breast cancer
Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
干预措施: Lumbar puncture
结局指标
主要结局
Percentage of eligible patients completing cerebrospinal fluid (CSF) evaluation
时间窗: 2 years
will require 8 out of 10 eligible patients to successfully complete the CSF evaluation
Number of eligible patients completing initial MRI
时间窗: 2 years
will require 8 out of 10 eligible patients to successfully complete the initial MRI